SCHEMBL1521583

SCHEMBL1521583

CSc1ncc2c(n1)N(C)C(=O)N(c1cc(N)c(F)cc1Cl)C2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 9/20 0.55
FGFR1 P11362 6/20 0.35
FGFR3 P22607 5/20 0.35
KDR P35968 4/20 0.35
TNK2 Q07912 4/20 0.35
MAP4K2 Q12851 4/20 0.35
BMX P51813 3/20 0.35
LCK P06239 2/20 0.35
ABL1 P00519 2/20 0.35
FES P07332 1/20 0.35
RET P07949 1/20 0.35
PDGFRB P09619 1/20 0.35
KIT P10721 1/20 0.35
SRC P12931 1/20 0.35
PDGFRA P16234 1/20 0.35
FLT1 P17948 1/20 0.35
EPHA3 P29320 1/20 0.35
EPHB4 P54760 1/20 0.35
TEK Q02763 1/20 0.35
KARS1 Q15046 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521938 0.89 FGFR4 (0.56) FGFR4FGFR1FGFR3KDRTNK2
SCHEMBL1521523 0.87 FGFR4 (0.41) FGFR4FGFR1FGFR3KDRTNK2
SCHEMBL1521642 0.85 FGFR4 (0.51) FGFR4FGFR1FGFR3KDRTNK2
SCHEMBL1521723 0.81 FGFR4 (0.66) FGFR4FGFR1FGFR3KDRTNK2
SCHEMBL3573608 0.77 FGFR4 (0.55) FGFR4FGFR1FGFR3KDRTNK2
SCHEMBL5229018 0.76 FGFR4 (0.61) FGFR4FGFR1FGFR3KDRLCK
SCHEMBL6618207 0.76 FGFR4 (0.61) FGFR4FGFR1FGFR3KDRTNK2
SCHEMBL1521590 0.76 FGFR4 (0.42) FGFR4FGFR1FGFR3KDRTNK2
SCHEMBL1521662 0.76 FGFR4 (0.42) FGFR4FGFR1FGFR3KDRTNK2
SCHEMBL1521518 0.76 FGFR4 (0.42) FGFR4FGFR1FGFR3KDRTNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 FGFR4 1073/4885FGFR1 577/4885FGFR3 811/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 FGFR4 1073/4885FGFR1 577/4885FGFR3 811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.